Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 225 7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

stockobserver Aug. 18 at 6:33 PM

$CNTX Is there a conversion going on.

1 · Reply

SpencerF Aug. 18 at 5:41 PM

$CNTX damn, back to no chance of making it again?

0 · Reply

stockobserver Aug. 18 at 4:47 PM

$CNTX Lots of pressure today

0 · Reply

Trendsetta69 Aug. 18 at 2:59 PM

$CNTX added 💎

0 · Reply

Swift_Trades Aug. 17 at 10:54 PM

$CNTX 💪

0 · Reply

J1476 Aug. 17 at 4:19 PM

$CNTX buys coming in

0 · Reply

stockobserver Aug. 17 at 3:39 PM

$CNTX Watching and slowly adding

0 · Reply

MKRReformed Aug. 17 at 2:18 PM

$HAO now up close to 40% from our sub .16 pre r/s entry. Holding a wad still

0 · Reply

Minecraftbeers Aug. 17 at 12:09 PM

$CNTX what’s with the massive drop on this stock?

0 · Reply

buymoremakemore Aug. 15 at 3:17 AM

$CNTX Great recovery this week. This stock is insanely mispriced. $1.50 possible before data readouts. And if either CITM-76 or CT-202 good then this gets a massive re-rating. 10x potential. This Philadelphia based stock has the spirit of Rocky Balboa.

0 · Reply

Context downgraded to Market Perform from Outperform at LifeSci Capital

2026-08-06T19:25:26.000Z - 12 days ago

Context Therapeutics price target lowered to $3 from $4 at Citizens

2026-08-05T22:05:21.000Z - 13 days ago

Context Therapeutics reports Q2 EPS (15c), consensus (9c)

Aug 5, 2026, 4:14 PM EDT - 13 days ago

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Aug 5, 2026, 7:00 AM EDT - 14 days ago

Context Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 14 days ago

Context Therapeutics Earnings release: Q2 2026

Aug 1, 2026, 8:00 AM EDT - 18 days ago

Context Therapeutics Slides: Corporate presentation

Jul 10, 2026, 4:05 PM EDT - 5 weeks ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 6, 2026, 4:07 PM EDT - 6 weeks ago

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

2026-06-16T13:16:11.000Z - 2 months ago

Context Therapeutics price target lowered to $4 from $8 at Maxim

2026-06-15T17:35:49.000Z - 2 months ago

Context Therapeutics selloff brings buying opportunity, says JonesResearch

ZYME

2026-06-15T16:30:38.000Z - 2 months ago

Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Context Therapeutics Transcript: Study result

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Context Therapeutics Press release: Study result

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Context Therapeutics Slides: Study result

2026-06-15T10:37:21.000Z - 2 months ago

Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial

Jun 15, 2026, 6:30 AM EDT - 2 months ago

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Jun 13, 2026, 7:00 AM EDT - 2 months ago

Context Therapeutics Slides: Corporate presentation

Jun 3, 2026, 7:35 AM EDT - 2 months ago

Context Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 7:30 AM EDT - 3 months ago

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

2026-05-18T10:54:19.000Z - 3 months ago

Context Therapeutics enters license agreement amendment with BioAtla

BCAB

May 18, 2026, 6:45 AM EDT - 3 months ago

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

2026-05-07T00:54:46.000Z - 3 months ago

Context Therapeutics reports Q1 EPS (9c), consensus (12c)

May 6, 2026, 4:18 PM EDT - 3 months ago

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

May 6, 2026, 7:00 AM EDT - 3 months ago

Context Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Context Therapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Context Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Context Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Context Therapeutics Proxy statement: Proxy filing

2026-04-02T11:54:29.000Z - 4 months ago

Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA

Apr 2, 2026, 7:30 AM EDT - 4 months ago

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

2026-03-24T10:35:12.000Z - 5 months ago

Context Therapeutics price target raised to $7 from $4 at Piper Sandler

Mar 23, 2026, 4:16 PM EDT - 5 months ago

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Context Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Context Therapeutics Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Context Therapeutics Slides: Corporate presentation

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 11, 2026, 9:20 AM EDT - 5 months ago

Context Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 6 months ago

Context Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 9, 2026, 7:30 AM EST - 6 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Jan 16, 2026, 4:05 PM EST - 7 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-12-22T12:16:26.000Z - 8 months ago

Context Therapeutics initiated with a Buy at JonesResearch

Nov 10, 2025, 3:00 PM EST - 10 months ago

Context Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T12:35:45.000Z - 10 months ago

Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting

Nov 7, 2025, 7:30 AM EST - 10 months ago

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

2025-11-06T11:11:21.000Z - 10 months ago

Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright

2025-11-05T23:00:43.000Z - 10 months ago

Context Therapeutics reports Q3 EPS (10c), consensus (9c)

Nov 5, 2025, 4:15 PM EST - 10 months ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Nov 5, 2025, 7:00 AM EST - 10 months ago

Context Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Context Therapeutics Quarterly report: Q3 2025

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Oct 6, 2025, 7:30 AM EDT - 11 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

2025-10-02T10:45:36.000Z - 11 months ago

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-02T10:05:17.000Z - 11 months ago

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-09-29T14:10:09.000Z - 11 months ago

Context Therapeutics management to meet with Maxim

2025-09-17T20:40:12.000Z - 11 months ago

Context Therapeutics initiated with a Buy at Guggenheim

Aug 6, 2025, 4:11 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Aug 6, 2025, 12:00 AM EDT - 1 year ago

Context Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 12:00 AM EDT - 1 year ago

Context Therapeutics Quarterly report: Q2 2025

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

May 29, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 7, 2025, 4:09 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 7, 2025, 12:00 AM EDT - 1 year ago

Context Therapeutics Earnings release: Q1 2025

May 7, 2025, 12:00 AM EDT - 1 year ago

Context Therapeutics Quarterly report: Q1 2025

May 5, 2025, 4:05 PM EDT - 1 year ago

Context Therapeutics Announces Chief Medical Officer Transition

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Context Therapeutics Proxy statement: Proxy Filing

Mar 26, 2025, 4:02 PM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 1 year ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Context Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Context Therapeutics Annual report: Q4 2024

Jan 14, 2025, 4:58 PM EST - 1 year ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 1 year ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 19, 2024, 1:50 PM EST - 1 year ago

Context Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 2:45 PM EST - 1 year ago

Context Therapeutics Transcript: UBS Global Healthcare Conference

Nov 11, 2024, 3:00 PM EST - 1 year ago

Context Therapeutics Transcript: Guggenheim Inaugural Global Healthcare Conference

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nov 6, 2024, 4:00 PM EST - 1 year ago

Context Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Context Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Context Therapeutics Registration statement: Registration Filing

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 2:00 PM EDT - 1 year ago

Context Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Context Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Context Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 24, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Proxy statement: Proxy Filing

Jul 24, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Proxy statement: Proxy Filing

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 24, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Registration statement: Registration Filing

May 8, 2024, 4:06 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

Context Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Context Therapeutics Earnings release: Q1 2024

May 2, 2024, 7:31 AM EDT - 2 years ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Context Therapeutics Annual report: Q4 2023

Mar 21, 2024, 7:43 AM EDT - 2 years ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 3 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 9, 2023, 7:00 AM EST - 3 years ago

Context Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Context Therapeutics Earnings release: Q3 2023

Sep 27, 2023, 9:00 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 3 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Context Therapeutics Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Context Therapeutics Earnings release: Q2 2023

Aug 1, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 3 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Context Therapeutics Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Context Therapeutics Earnings release: Q1 2023

Apr 18, 2023, 10:15 AM EDT - 3 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Context Therapeutics Proxy statement: Proxy Filing

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Context Therapeutics Proxy statement: Proxy Filing

Mar 22, 2023, 5:08 PM EDT - 3 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Context Therapeutics Earnings release: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Context Therapeutics Annual report: Q4 2022

Mar 15, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

stockobserver Aug. 18 at 6:33 PM

$CNTX Is there a conversion going on.

1 · Reply

SpencerF Aug. 18 at 5:41 PM

$CNTX damn, back to no chance of making it again?

0 · Reply

stockobserver Aug. 18 at 4:47 PM

$CNTX Lots of pressure today

0 · Reply

Trendsetta69 Aug. 18 at 2:59 PM

$CNTX added 💎

0 · Reply

Swift_Trades Aug. 17 at 10:54 PM

$CNTX 💪

0 · Reply

J1476 Aug. 17 at 4:19 PM

$CNTX buys coming in

0 · Reply

stockobserver Aug. 17 at 3:39 PM

$CNTX Watching and slowly adding

0 · Reply

MKRReformed Aug. 17 at 2:18 PM

$HAO now up close to 40% from our sub .16 pre r/s entry. Holding a wad still

0 · Reply

Minecraftbeers Aug. 17 at 12:09 PM

$CNTX what’s with the massive drop on this stock?

0 · Reply

buymoremakemore Aug. 15 at 3:17 AM

0 · Reply

Trendsetta69 Aug. 15 at 1:34 AM

$CNTX this will make a run

0 · Reply

Swift_Trades Aug. 14 at 9:27 PM

$CNTX BIG MONEY COMING. ✊

1 · Reply

MKRReformed Aug. 14 at 7:22 PM

$CNTX $HAO beautiful days here as expected Hao 30% move now in a day when r/s conversion accounted for

0 · Reply

NGupup Aug. 14 at 3:11 PM

$CNTX YES go up⬆️🔥

0 · Reply

MKRReformed Aug. 14 at 2:33 PM

Both up nicely ($HAO obviously is showing the post split roi but it’s now hitting 20% from pre adjustment fill at .16). Holding some of both over weekend $CNTX

0 · Reply

Swift_Trades Aug. 13 at 10:12 PM

$CNTX 👀👀👀

0 · Reply

J1476 Aug. 13 at 8:01 PM

$CNTX @Slimeflu hope you loaded up on that dip buddy

0 · Reply

NGupup Aug. 13 at 7:49 PM

$CNTX GO IN SPACE ⬆️⬆️😁

0 · Reply

MKRReformed Aug. 13 at 5:09 PM

$CNTX $HAO have these two Penny plays on scanner or watchlist No entry yet but abnormal volume

0 · Reply

Swift_Trades Aug. 13 at 4:36 PM

$CNTX 🚨🚨🚨

0 · Reply

Ebooks Aug. 13 at 4:30 PM

$CNTX Liking this accumulation...level 2 pretty empty tilll .60....would love to see a breakout over this...GLTA

0 · Reply

Swift_Trades Aug. 13 at 4:13 PM

$CNTX 💣⏰

0 · Reply

Market Cap	48.72M
Revenue (ttm)	0.00
Net Income (ttm)	-36.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,332,900
Avg Vol	3,056,274
Day's Range	N/A - N/A
Shares Out	91.88M
Stochastic %K	60%
Beta	1.74
Analysts	Strong Sell
Price Target	$4.88